The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma

PurposeThe human gene PTPN11, which encodes the non-receptor protein tyrosine phosphatase of Src homology phosphotyrosine phosphatase 2 (Shp2), has been previously well interpreted as a proto-oncogene in a variety of malignancies. However, the tumor suppressor role of Shp2 has also been reported. The present study was conducted to investigate the role of Shp2 expression and its associated clinical manifestations in hepatocellular carcinoma (HCC).MethodsA tissue microarray of 333 pairs of HCC and self-matched adjacent non-tumor tissues was constructed, and the expression of Shp2 was determined by immunohistochemistry. The results were also conformed by Western blotting and quantitative PCR of 31 self-paired fresh HCC specimens. The associations of Shp2 expression with 25 clinicopathologic features were analyzed. Overall survival analysis and multivariate analysis were performed.ResultsSignificantly decreased Shp2 expression in tumor tissues (T) compared with adjacent non-tumor tissues (NT) could be detected, and the positive rate was 66.1 and 96.7%, respectively. We combined the T and NT Shp2 immunoreactivity by a variable of the decrease in Shp2 expression (ΔShp2) and divided cases into 2 groups: T < NT and T ≥ NT. Survival analysis showed both low Shp2 expression and T < NT group were significantly associated with short overall survival. Multivariate analysis showed ΔShp2 was an independent prognostic marker (P = 0.033; HR: 0.527; 95% CI: 0.293–0.950).ConclusionShp2 is a tumor suppressor, and the decrease in Shp2 expression was a new prognostic marker in HCC. The oncogenic role of Shp2 was tissue specific, and the therapeutic target of human gene PTPN11 should be reconsidered.

[1]  Y. Agazie,et al.  Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells , 2008, Cell Death and Differentiation.

[2]  T. Mustelin,et al.  IMMUNOHISTOCHEMICAL ANALYSES OF PHOSPHATASES IN CHILDHOOD B-CELL LYMPHOMA: Lower Expression of PTEN and HePTP and Higher Number of Positive Cells for Nuclear SHP2 in B-Cell Lymphoma Cases Compared to Controls , 2008, Pediatric hematology and oncology.

[3]  G. Feng,et al.  PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. , 2007, Blood.

[4]  S. Sheen-Chen,et al.  Yes-associated protein is not an independent prognostic marker in breast cancer. , 2012, Anticancer research.

[5]  T. Matozaki,et al.  Protein tyrosine phosphatase SHP‐2: A proto‐oncogene product that promotes Ras activation , 2009, Cancer science.

[6]  S. Kondo,et al.  Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors , 2008, Oncogene.

[7]  Shu Zheng,et al.  SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer. , 2011, World journal of gastroenterology.

[8]  B. Neel,et al.  The tyrosine phosphatase Shp2 (PTPN11) in cancer , 2008, Cancer and Metastasis Reviews.

[9]  T. Han,et al.  Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. , 2011, Cancer cell.

[10]  B. Casserly,et al.  Role of protein tyrosine phosphatase SHP2 in barrier function of pulmonary endothelium. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[11]  Young-Seok Cho,et al.  Overexpression of Protein Phosphatase Non-receptor Type 11 (PTPN11) in Gastric Carcinomas , 2010, Digestive Diseases and Sciences.

[12]  D Nicholson,et al.  Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. , 1990, Cancer research.

[13]  Tao Zhou,et al.  Deactivation of the kinase IKK by CUEDC2 through recruitment of the phosphatase PP1 , 2008, Nature Immunology.

[14]  C. Hellberg,et al.  Protein-tyrosine phosphatases and cancer , 2006, Nature Reviews Cancer.

[15]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[16]  S. Lowe,et al.  Yes‐associated protein is an independent prognostic marker in hepatocellular carcinoma , 2009, Cancer.

[17]  Malcolm McGregor,et al.  Diverse Biochemical Properties of Shp2 Mutants , 2005, Journal of Biological Chemistry.